Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Clin Transl Oncol. 2018 May 7;20(11):1474–1483. doi: 10.1007/s12094-018-1888-2

Table 2.

MK-2206 Adverse Events

Dose Level (# of Patients) Adverse Event Grade I Grade II Grade III
200 mg (4)
Mucositis 1 2
Rash 1 1
Pruritus 2
Hyperglycemia 1 1
Fever 1
135 mg (3)
Rash 2
Pruritus 1 1
90 mg (5)
Mucositis 1 1
Rash 1
Hyperglycemia 1
Dry Skin 2
Total (12) 6 7 7